Gilead Sciences Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GILEAD SCIENCES, and what generic alternatives to GILEAD SCIENCES drugs are available?
GILEAD SCIENCES has twenty-two approved drugs.
There are seventy-eight US patents protecting GILEAD SCIENCES drugs.
There are two thousand and thirty-eight patent family members on GILEAD SCIENCES drugs in sixty-three countries and three hundred and twenty-two supplementary protection certificates in nineteen countries.
Summary for Gilead Sciences
International Patents: | 2038 |
US Patents: | 78 |
Tradenames: | 18 |
Ingredients: | 18 |
NDAs: | 22 |
Patent Litigation for Gilead Sciences: | See patent lawsuits for Gilead Sciences |
PTAB Cases with Gilead Sciences as patent owner: | See PTAB cases with Gilead Sciences as patent owner |
Drugs and US Patents for Gilead Sciences
Expired US Patents for Gilead Sciences
Paragraph IV (Patent) Challenges for GILEAD SCIENCES drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg/25 mg/300 mg | ➤ Subscribe | 2015-05-20 |
➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
➤ Subscribe | Tablets | 600 mg/200 mg/300 mg | ➤ Subscribe | 2008-12-29 |
➤ Subscribe | Tablets | 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-05-17 |
➤ Subscribe | Tablets | 150 mg, 150 mg, 200 mg, 300 mg | ➤ Subscribe | 2018-10-04 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2010-01-26 |
International Patents for Gilead Sciences Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 101664154 | See Plans and Pricing |
Poland | 2487166 | See Plans and Pricing |
Australia | 2017202461 | See Plans and Pricing |
Hungary | 0301307 | See Plans and Pricing |
Canada | 2611520 | See Plans and Pricing |
Hungary | S1500052 | See Plans and Pricing |
Israel | 244122 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Gilead Sciences Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1419152 | PA2012008,C1419152 | Lithuania | See Plans and Pricing | PRODUCT NAME: RILPIVIRINUM; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 |
2430014 | 92956 | Luxembourg | See Plans and Pricing | PRODUCT NAME: LEDIPASVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/958 20141118 |
1419152 | CA 2012 00021 | Denmark | See Plans and Pricing | |
1663240 | 223 5021-2015 | Slovakia | See Plans and Pricing | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 |
2487166 | 17C1001 | France | See Plans and Pricing | PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET TENOFOVIR ALAFENAMIDE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/15/1061 20151123 |
2487162 | C20170003 00221 | Estonia | See Plans and Pricing | PRODUCT NAME: DARUNAVIIR/KOBITSISTAAT;REG NO/DATE: EU/1/14/967 21.11.2014 |
2430014 | 4/2016 | Austria | See Plans and Pricing | PRODUCT NAME: LEDIPASVIR; REGISTRATION NO/DATE: EU/1/14/958 (MITTEILUNG) 20141118 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.